GeoVax CEO to Present at ROTH Healthcare Conference, Highlighting Vaccine and Cancer Therapy Pipeline
GeoVax Labs' participation in the ROTH Healthcare Opportunities Conference provides investors with insights into the company's advancing vaccine and cancer therapy pipeline, including progress on Mpox, COVID-19 vaccines, and oncology treatments.
GeoVax Labs, Inc. announced that Chairman and CEO David Dodd will participate in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Yale Club in New York City. The conference serves as a platform for healthcare companies to connect with institutional investors through one-on-one meetings and panel discussions. This participation comes at a critical time as GeoVax advances multiple clinical programs that address significant public health challenges.
During the conference, Dodd will discuss the company's pipeline progress, including GEO-MVA, an MVA-based Mpox/smallpox vaccine that recently received favorable Scientific Advice from the European Medicines Agency. This regulatory guidance positions the vaccine to potentially advance directly to Phase 3 clinical evaluation, bypassing earlier trial phases and accelerating its development timeline. The vaccine is positioned to support global preparedness and stockpile strategies for poxvirus threats.
The company's COVID-19 vaccine candidate, GEO-CM04S1, represents another key program currently being evaluated in three Phase 2 clinical trials across various patient populations. This multi-antigen vaccine is being studied as both a primary vaccine for immunocompromised patients and as a booster for healthy adults who previously received mRNA vaccines. The program addresses critical gaps in current COVID-19 vaccination strategies, particularly for vulnerable populations where existing vaccines may provide insufficient protection.
In oncology, GeoVax is advancing Gedeptin®, a gene-directed enzyme prodrug therapy for solid tumors, with a planned Phase 2 trial in head and neck cancer. This therapeutic approach represents an innovative strategy for treating challenging cancer types where current treatment options remain limited. The company's progress in this area comes at a time when novel cancer therapies are increasingly important for improving patient outcomes.
The ROTH Healthcare Opportunities Conference provides an important venue for institutional investors to gain detailed insights into GeoVax's development strategy and upcoming milestones. The one-on-one and small group meeting format allows for extensive interaction between management and investors, offering deeper understanding of the company's progress across its diverse pipeline. For more information about the company's clinical programs and development status, visit https://www.geovax.com.
GeoVax's participation in this high-profile investment conference underscores the growing importance of its clinical programs in addressing both infectious disease threats and cancer treatment challenges. The company's diverse pipeline, spanning from preventative vaccines to cancer therapies, positions it to potentially impact multiple areas of significant medical need. The favorable regulatory feedback received for the Mpox/smallpox vaccine program represents a notable validation of the company's development approach and technology platform.